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Abstract: Understanding the potential for adverse drug reactions (ADRs), from herb-drug 
interactions, is a key aspect of medicinal plant safety, with particular relevance for public health in 
countries where medicinal plant use is highly prevalent. We undertook an in-depth assessment of 
extracts of Hyptis verticillata Jacq., via its impact on activities of key cytochrome P450 (CYP) enzymes 
(CYPs 1A1, 1A2, 1B1, 3A4 and 2D6), its antioxidant properties (determined by DPPH assays) and 
chemical characterisation (using LC-MS). The dried plant aqueous extract demonstrated potent 
inhibition of the activities of CYPs 1A1 (7.6 µg/mL), 1A2 (1.9 µg/mL), 1B1 (9.4 µg/mL) and 3A4 (6.8 
µg/mL). Further analysis of other crude extracts demonstrated potent inhibition of CYP1A2 activity 
for a dried plant ethanol extract (1.5 µg/mL), fresh plant ethanol extract (3.9 µg/mL), and moderate 
activity for a fresh plant aqueous extract (27.8 µg/mL). All four extracts demonstrated strong 
antioxidant activity, compared to the positive control (ascorbic acid, 1.3 µg/mL), with the dried plant 
ethanol extract being the most potent (1.6 µg/mL). Analysis of the dried plant aqueous extract 
confirmed the identity of seven phytochemicals, five lignans and two triterpenes. Individual 
screening of these phytochemicals against the activity of CYP1A2 identified yatein as a moderate 
inhibitor (71.9 µM), likely to contribute to the plant extract’s potent bioactivity. Further analysis on 
the impact of this plant on key drug metabolizing enzymes in vivo appears warranted for likely 
ADRs, as well as furthering development as a potential chemopreventive agent. 
Keywords: cytochrome P450; Hyptis verticillata Jacq.; enzyme inhibition; herb-drug interaction; 
drug-herb interaction; adverse drug reaction; ADR; chemoprevention; antioxidant 
 
1. Introduction 
The use of medicinal plants continues to be high, with the World Health Organisation (WHO) 
estimating 80% prevalence in developing countries [1], and many people continuing to rely on them 
as their main or only type of primary healthcare [2]. We previously reported that 73% of Jamaican 
adults use medicinal plants to treat illness and maintain health [3]. From the same research, we also 
reported that 27% of Jamaican medicinal plant users take pharmaceutical drugs concomitantly. A 
survey of cancer patients attending the oncology and urology clinics at the University Hospital of the 
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West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high 
levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-
drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] 
and 19% [3], respectively). High levels of concomitant herb-drug use and low physician awareness 
are reported elsewhere. For example, a survey of 381 patients in Norwegian general practice reported 
44% prevalence for medicinal plant use, 45% concomitant use with pharmaceutical drugs, and 25% 
awareness amongst attending physicians [7].  
Adverse drug reactions (ADRs) resulting from the altered metabolism of one drug caused by the 
interaction of a second drug are well researched and documented [8]. Herb-drug interactions, 
however, are far less researched, particularly in developing countries, where medicinal plant use is 
most prevalent [1,3]. Understanding the clinical impact and potential risk of ADRs, resulting from 
herb-drug interactions, is a critical public health issue, and a key aspect of medicinal plant safety. 
However, most of the plant-based research, to date, has been completed in developed countries, 
predominantly using in vitro studies, but, also with increasing numbers of clinical studies. Clinical 
studies of some of the most commonly researched plants include garlic (Allium sativum), St. John’s 
wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].  
Our laboratory has been working to address both the imbalance in research output from the 
Caribbean, and the potential public health risk, by testing medicinal plants, commonly used in 
Jamaica, for their impact on key drug metabolizing enzymes [10–12]. Plants tested include Artocarpus 
altilis [13], Peperomia pellucida [14], Petiveria alliacea [15] and Picrasma excelsa [16].  
This latest study set out to investigate the inhibitory impact of various extracts of H. verticillata 
on a number of key drug metabolizing CYP450 enzymes, its characterisation and further impact on 
CYP1A2, representing the first such in vitro evaluation for this plant, and to add to the growing list 
of screened Caribbean medicinal plants. CYP1 inhibitions and associated antioxidant activities have 
also been linked with chemopreventive potential and thus we also carried out an in vitro antioxidant 
screen [8]. H. verticillata was previously identified as one of the top 25 medicinal plants used by 
Jamaicans in a TRAMIL survey [3,17]. TRAMIL, a Caribbean-wide applied research programme, 
scientifically evaluates and documents the efficacy and safety of medicinal plant remedies used for 
primary healthcare [18]. An earlier comprehensive review of this plant details its extensive traditional 
uses, phytochemistry pharmacology and toxicology [19]. For example, traditional uses documented 
in Jamaica include, bronchitis, cold, colic, fever, indigestion, itchy skin, mucous congestion, arthritis, 
tonsillitis, and fibroids [19]. In our earlier survey, documenting concomitant use, respondents 
identified their use of H. verticillata in combination with a number of pharmaceutical drugs, including 
aspirin, hydralazine, hydrochlorothiazide, and metformin. Respondents identified using H. 
verticillata for different health conditions to those for which they were prescribed a pharmaceutical 
drug(s) [3].  
2. Results 
2.1. Inhibition of CYP Activity by Aqueous Extract of Dried Aerial Plant Material  
The impact of an aqueous extract of the dried aerial plant on the activities of a number of CYP 
enzymes was investigated, and a summary of the results shown in Figures 1A,B. Best-fit non-linear 
plots were fitted to the data points using the 4-parameter logistic (4PL) non-linear regression model 
(SigmaPlot) and IC50 values determined for four of the five enzymes tested. The aqueous extract of 
H. verticillata potently inhibited the activity of all four enzymes, with the concentration needed to 
inhibit 50% of activity, IC50 values all being under 10 µg/mL: CYPs 1A2 (1.9 µg/mL), 1A1 (7.6 µg/mL), 
1B1 (9.4 µg/mL) and 3A4 (6.8 µg/mL). It was not possible to measure the aqueous extract’s impact on 
CYP2D6 due to a high level of background fluorescence produced by the extract (Figures 1A,B). 
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Figure 1. (A) Impact of H. verticillata aqueous extract on CYP activities. Human CYPs 1A1, 1A2 
catalyzed 7-ethoxy-3-cyanocoumarin (CEC) (0.5, 5.0 µM respectively) metabolism, CYP1B1 catalyzed 
7-ethoxyresorufin (ERes) (0.37 µM) metabolism and CYP3A4 catalyzed 7-benzyloxy-4-
trifluoromethylcoumarin (BFC) (50 µM) metabolism were determined in the presence of varying 
concentrations of reconstituted freeze-dried aqueous extract of H. verticillata ranging from 0.02 to 575 
µg/mL, as described in the Materials and Methods section. Control enzyme activity (mean ± SEM) for 
CYPs 1A1, 1A2, 1B1 and 3A4 was 1.43 ± 0.2, 1.49 ± 0.001, 0.95 ± 0.001 and 0.86 ± 0.000 (µM/min/pmol) 
of CYP, respectively. Data are expressed as mean percentage of enzyme activity for experiments 
carried out in triplicate; (B) Summary of results. 
2.2. Inhibition of CYP1A2 Activity by Different Crude Extracts of H. verticillata (Aerial Plant) 
Best-fit non-linear plots were fitted to the data points using the 4-parameter logistic (4PL) non-
linear regression model (SigmaPlot) and IC50 values determined for four aerial plant extracts, aqueous 
dried and fresh and ethanol, dried and fresh. Both fresh and dry ethanol extracts and the dry aqueous 
extract demonstrated potent inhibition of CYP1A2 activity with the dry plant ethanol extract 
demonstrating the most potent inhibition (1.5 µg/mL). The dry aqueous extract potently inhibited 
CYP1A2 activity and was close in potency at 1.9 µg/mL to the dry plant ethanol extract and was more 
potent than the fresh plant ethanol extract (3.9 µg/mL). The fresh plant aqueous extract moderately 
inhibited CYP1A2 activity (27.8 µg/mL). 
2.3. Antioxidant Assays 
The 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay was used to measure the antioxidant capacity 
of four different extracts of the aerial parts of H. verticillata (Figure 2). The reduction of DPPH to 
hydrazine produces a colour change from purple to yellow, which is measured 
spectrophotometrically and compared with the known antioxidant, ascorbic acid, as described in the 
Materials and Methods section. 
All four extracts demonstrated strong antioxidant activity in comparison to the positive control, 
with the ethanol dried plant extract showing the most potent activity, almost directly comparable to 
that of ascorbic acid (Figure 2). 
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Figure 2. (A) DPPH antioxidant assay for H. verticillata extracts. Antioxidant capacity was determined 
in the presence of varying concentrations of reconstituted freeze-dried aqueous extracts and ethanol 
extracts of H. verticillata from both fresh and dry aerial plant material ranging from 0.097 to 50 µg/mL, 
as described in the Materials and Methods section. Positive control activity was determined in the 
presence of varying concentrations of known antioxidant, ascorbic acid, ranging from 0.097 to 50 
µg/mL. Data are expressed as Mean Percentage Antioxidant Activity (% Inhibition of DPPH) for 
duplicate assays for at least two independent experiments. (B) Summary of results. 
2.4. Standardization of Dried Aerial Plant Aqueous Extract by RP-HPLC and LC-MS  
2.4.1. RP-HPLC 
An initial separation of the aqueous extract of H. verticillata (dried aerial material) was 
undertaken using RP-HPLC, through which fractions were collected using a Gilson FC 203B fraction 
collector and concentrated on a Savant SpeedVac concentrator (Appendix A, Figure A1), and 
subsequent analysis undertaken using LC-MS (Appendix B, Table A1), as described in the Materials 
and Methods section. 
2.4.2. LC-MS 
The exact mass to charge ratio (m/z) values of all ion species detected by a high resolution LC-
MS were recorded, interpreted, and compared with the molecular weights of all known metabolites 
that have been identified to date for the aerial parts of H. verticillata [19–21] and fifteen potentially 
positive spectral results were identified (Table 1) (Appendix B, Table A1). In each case, mass 
differences between calculated and measured were within calibrant tolerance. The use of exact mass 
and adduct measurement confirms in most cases the identity of the compounds. 
The fifteen LC-MS spectral results cross-referenced with data from the RP-HPLC analysis using 
standards (Table 1) (Appendix A, Figures A1 and A2 & Appendix B, Table A1) confirmed the 
presence of five lignans, deoxydehydropodophyllotoxin, 4′-demethylpodophyllotoxin, (-)-yatein, 
dehydropodophyllotoxin and podophyllotoxin (Table 1, Figure 3). RP-HPLC analysis with standards 
alone, confirmed the presence of one further phytochemical, the triterpene oleanolic acid (Table 1, 
Figure 3) (Appendix A, Figure A2 and Appendix B, Table A1). 
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Figure 3. Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried). 
Table 1. LC-MS * and RP-HPLC analysis and summary. 
Phytochemicals Identified in H. 
verticillata by LC-MS  
Empirical 
Formula
Mono-isotopic 
Mass (Da) 1
Confirmation by RP-
HPLC Standard 
Cadina-10(15)-en-3-one C15H22O 218.167  
Aromadendr-1(10)-en-9-one  C15H22O 218.167  
7,11,15-Trimethyl-3-methylenehexadecane
-1,2-diol  C20H40O2 312.303  
Rosmarinic acid  C18H16O8 360.315  
Deoxydehydropodophyllotoxin 2  C22H18O7 394.105 (+) 
Dehydrodesoxypodophyllotoxin  C22H18O7 394.105  
ß-Apopicropodophyllin  C22H20O7 396.121  
Hyptinin  C22H20O7 396.121  
Isodeoxypodophyllotoxin  C22H22O7 398.136  
Deoxypicropodophyllin  C22H22O7 398.136  
4-Demethylpodophyllotoxin  C21H20O8 400.116 (+) 
(-)-Yatein  C21H20O8 400.152 (+) 
Dehydropodophyllotoxin 2 C22H18O8 410.100 (+) 
Podophyllotoxin  C22H22O8 414.131 (+) 
ß-Peltatin  C22H22O8 414.131  
Oleanolic acid 3 C30H48O3 456.360 (+) 
1 ChemSpider—Royal Society of Chemistry; 2 Lignans in the five lignan mix supplied by UWI Dept. 
of Chemistry; (+) tested and confirmed to be present using HPLC analysis with the relevant standard; 
Bold—five phytochemicals identified through both LC-MS and RP-HPLC analysis; 3 Phytochemical 
identified through RP-HPLC alone; * Exact mass measurements using a High Resolution instrument 
(Waters LCT ToF MS, with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software) 
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2.5. Inhibition of CYP1A2 Activity by Key Phytochemicals Present in H. verticillata  
Key phytochemicals were individually assessed for their impact on CYP1A2 activity. Best-fit 
non-linear plots were fitted to the data points using the 4-parameter logistic (4PL) non-linear 
regression model (SigmaPlot) and IC50 values determined, where possible. Calculated and/or 
estimated IC50 values are summarized in Table 2.  
2.5.1. Key Phytochemicals—Mixed Lignans, (-)-Yatein and β-Sitosterol  
The mix of five lignans demonstrated moderate inhibition against the activity of CYP1A2 (61.8 
µg/mL). In comparison H. verticillata aqueous extract (dried aerial plant material) demonstrated 
potent inhibition of CYP1A2 activity (1.9 µg/mL). The IC50 values determined for (-)-yatein (71.9 µM), 
demonstrated moderate inhibition, and β-sitosterol (160.1 µM) demonstrated weak inhibition against 
the activity of CYP1A2. In comparison, the plot and the IC50 value for known CYP1A2 inhibitor, 
furafylline (1.4 µM), demonstrated potent inhibition (Table 2).  
2.5.2. Key Phytochemicals—Oleanolic and Ursolic acid, Cadina-4,10(15)-Dien-3-One, 
Podophyllotoxin, 4′-Demethylpodophyllotoxin and Rosmarinic Acid 
It was not possible to determine the IC50 values for oleanolic and ursolic acid or cadina-4,10(15)-
dien-3-one. However, it was possible to indicate that IC50 values for both oleanolic and ursolic acid 
would be >100 µM and for cadina-4,10(15)-dien-3-one >500 µM, demonstrating weak inhibition 
against the activity of CYP1A2 (Table 2). Two phytochemicals, podophyllotoxin and 4′-
demethylpodophyllotoxin demonstrated no impact on the activity of CYP1A2 (Table 2). It was not 
possible to plot a graph for rosmarinic acid, due to significant levels of metabolite quenching (>20%) 
even at lower concentrations (Table 2). 
2.5.3. Inhibition of CYP1A2 Activity—Summary 
Table 2. IC50 values of the aqueous extract of H. verticillata and key phytochemicals and their impact 
on metabolism mediated by CYP1A2. 
Test Phytochemical 
Concentration Range 
Tested [µg/mL] 
Solvent
(Highest % v/v) 
IC50 (µg/mL) 
H. verticillata aqueous extract 
(dried aerial material)  
0.25–60 H2O 1.9 ± 0.5 
Lignan Mix 0.08–180 DMF (2.0) 61.8 ± 0.7 
-Dehydropodophyllotoxin  
-Deoxydehydropodophyllotoxin  
-4′-Demethyldesoxypodophyllotoxin  
-5′-Methoxydehydropodophyllotoxin  
-Dehydro-β-peltatin methyl ether  
   
Test Phytochemical 
Concentration Range 
Tested [µM] 
Solvent
(Highest % v/v) 
IC50 (µM) 
Podophyllotoxin  2.9–369 DMF (0.7) No inhibition 
4′-Demethylpodophyllotoxin   0.28–611 DMF (0.7) No inhibition 
(-)-Yatein  0.18–400 DMF (1.2) 71.9 ± 1.8 
Cadina-4,10(15)-dien-3-one  0.28–623 H2O >500 
Oleanolic acid  0.9–219 DMF (1.3) >100 
Ursolic acid 0.05–117 DMF (1.8) >100 
β-Sitosterol 5.1–410 DMF (2.0) 160 ± 3.4 
Furafylline—reference inhibitor 0.04–96  1.4 ± 0.15 
3. Discussion 
In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for 
gauging the potential for herb-drug interactions. They are useful for initial risk assessment of 
medicinal plants capable of causing adverse drug reactions (ADRs) when taken concomitantly with 
pharmaceutical drugs metabolised by the same enzyme [22].  
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CYPs 1A2, 2D6, and 3A4 are three of the key enzymes involved in drug metabolism, and 
together, are responsible for the CYP mediated metabolism of approximately 83% of marketed 
pharmaceuticals. Broken down, the figures are 50% for CYP3A4, 25% for CYP2D6, and 8% for 
CYP1A2 [23]. CYP3A4 is the enzyme most implicated in drug interactions, while CYP2D6 is 
important, firstly because of the high percentage of drugs metabolized and secondly, because the 
enzyme is associated with high levels of polymorphism [8,24]. CYP1A2 is important, as it metabolizes 
many commonly prescribed drugs including the bronchodilator theophylline, the tricyclic 
antidepressant imipramine, the beta blocker propranolol and the antipsychotic clozapine [24].  
Published results, including those previously reported from our laboratory, point to a general 
consensus on the levels of inhibition that constitute potent, moderate, and weak inhibition in relation 
to the in vitro inhibition of crude extracts of medicinal plants on human CYP enzymes [15,16,25]: 
Potent: ≤9.9 µg/mL; Moderate (mild): 10–99.9 µg/mL; Weak: ≥100 µg/mL.  
The crude dried aerial aqueous extract of H. verticillata demonstrated potent inhibition against 
the activity of all four CYP enzymes successfully screened, CYPs 1A1, 1A2, 1B1 and 3A4 (Figure 1). 
Such potent inhibition against recombinant CYP enzymes points to the potential for metabolism-
based drug interactions in vivo and requires further investigation for confirmation of clinical 
relevance. In vitro indications are accepted as a useful initial screen for selecting potential candidates 
worthy of in vivo evaluations.  
Additional research, undertaken to assess the bioactivity of other traditionally prepared extracts, 
aqueous (fresh) and ethanol (dry and fresh), against the activity of the CYP enzyme most potently 
inhibited, in this case CYP1A2, demonstrated similar results to those originally obtained with the 
aqueous extract (dry plant material). The exception was the moderate level of inhibition seen for the 
aqueous extract of the fresh plant material (27.8 µg/mL). This is most likely due to the lower 
concentration of plant material on a weight by volume basis in the aqueous extract prepared with 
fresh plant material. Fresh plant material has a higher water content, and as a result approximately 
3–4 g of fresh plant material is required to provide the equivalent weight of 1 g of dried material [26]. 
CYP1A2 is an important enzyme, because it is responsible for metabolizing a number of 
commonly prescribed drugs, several of which are used in psychiatric medicine—drugs such as 
fluvoxamine, amitriptyline, clomipramine and clozapine. Several of these drugs have narrow 
therapeutic ranges, which consequently increases the risk of serious ADRs when interactions occur 
[23]. The potent inhibition of this important drug metabolizing enzyme by the aqueous (dried aerial 
material) and ethanol (fresh and dried aerial material) extracts of H. verticillata indicate the potential 
for pharmacokinetic metabolism-based drug interactions and warrants further in vivo investigations 
[8,27]. 
In addition, certain CYP enzymes, particularly the CYP1 family, play a role as potential cancer 
promoting agents. Potent inhibitors of these enzymes, in vitro, have chemopreventive potential in 
vivo, and warrant further investigation [28–31]. CYP1A1 is particularly implicated in lung, colorectal, 
breast, and prostate cancers, CYP1B1 in hormone dependent cancers of the prostate, breast, and 
endometrium, and CYP1A2 in colorectal, lung, and breast cancers [29,31,32]. Selectivity is an 
important criterion in short-listing plants for further assessment. It is notable that natural products 
successfully patented for their potential therapeutic value tend to demonstrate high selectivity in 
their inhibition of specific CYP activities [33]. 
Such likely chemopreventive properties are often corroborated by the antioxidant activities 
displayed by extracts. The four tested extracts demonstrated strong DPPH scavenging activity with 
IC50 values ranging from 1.6 µg/mL to 7.4 µg/mL (Figure 2). This strong antioxidant activity, together 
with the plant’s potent in vitro inhibition of CYPs 1A1 and 1B1 (Figure 1), known to be potent 
activators of carcinogens, points to potential chemopreventive properties and warrant further in vivo 
investigation [8,28–31].  
Similar antioxidant research on a number of other plants from the Lamiaceae family, reported 
IC50 values ranging from 3–44 µg/mL. Plant material was prepared using aerial dried samples in 
ethanol and results were compared to the reference antioxidant, Trolox (a vitamin E analog) (1.99 
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µg/mL), using the DPPH assay. One of the plants reported, Rosmarinus officinalis, often used as a 
positive control for antioxidant research, had an IC50 value of 5.0 µg/mL [34]. 
The antioxidant activity of H. verticillata was previously reported by Williams et al. [35] for 
extracts prepared from dried aerial plant material in ethanol and using the DPPH assay. On this 
occasion, the researchers reported antioxidant activity as percentage activity relative to control with 
reported results ranging from 0% to 96%. Of the plants screened, seven were from the Lamiaceae 
family and their reported antioxidant activities ranged from 17% to 55% with H. verticillata and 
Rosmarinus officinalis both reporting antioxidant activities of 55%. 
Further investigations were undertaken to characterise the phytochemicals in the crude aqueous 
extract of the dried aerial plant material of H. verticillata, to identify the key phytochemical(s) 
responsible for the inhibition of CYP1A2, and to allow further assessment of the plant preparation’s 
potential to impact the activities of CYP enzymes in vivo. 
The combined use of RP-HPLC and LC-MS confirmed the presence of five phytochemicals. 
These were the five lignans, podophyllotoxin, 4′-demethylpodophyllotoxin, (-)-yatein, 
dehydropodophyllotoxin and deoxydehydropodophyllotoxin, the latter two being part of the five-
lignan mixture (Table 1, Figure 3).  
The presence of the triterpene, oleanolic acid was confirmed by RP-HPLC alone (Table 1, Figure 
3). The two triterpenes, oleanolic acid and ursolic acid exist as regioisomers, with the only difference 
between them being the position of one methyl group. Whilst ursolic acid was not directly analysed 
to confirm its presence, based on the reports that both triterpenes exist together in plants 
simultaneously, it is highly likely that ursolic acid is also present [36,37].  
Five individual phytochemicals, together with the mixture of five lignans were tested for their 
impact on the activity of CYP1A2. The lignan mix and one individual phytochemical, (-)-yatein, 
demonstrated moderate/weak inhibition, with IC50 values of 61.8 µg/mL and 71.9 µM, respectively. 
The two triterpenes, oleanolic acid and ursolic acid, demonstrated weak inhibition, with IC50 values 
>100 µM. The remaining two individual phytochemicals, the lignans podophyllotoxin and 4-
demethylpodophyllotoxin demonstrated no inhibition of CYP1A2 activity (Table 2).  
Two further phytochemicals, cadina-4,10(15)-dien-3-one and ß–sitosterol were found to be weak 
inhibitors of CYP1A2 (Table 2). Their presence was ruled out through RP-HPLC screening with 
standards, however if they had been found to be present, their weak inhibition would indicate that 
they would not have contributed to the potent inhibition seen with the aqueous extract of H. 
verticillata (dried aerial plant). 
By way of comparison, an assay with a known CYP1A2 inhibitor, furafylline, was tested against 
the activity of CYP1A2, and an IC50 value of 1.4 ± 0.15 µM generated, which was consistent with values 
previously obtained and published by our laboratory (Table 2) [15]. 
Table 3 summarises the impact of a number of the key phytochemicals, identified in the aqueous 
extract of H. verticillata (dried aerial material), on CYP enzyme activity where this has been 
independently reported in the literature. Only two of the phytochemicals, oleanolic and ursolic acid, 
appear to have been previously screened against the activity of CYP1A2 [38]. In both cases, the 
reported inhibition was weak, >100 µM, in line with the results now being reported in our laboratory. 
Podophyllotoxin and (-)-yatein are reported as potent inhibitors of CYP3A4 [39,40] and (-)-yatein 
is reported as a moderate/weak inhibitor against the activity of CYP2D6 [39] (Table 3). Our results, 
reporting no inhibition by podophyllotoxin and moderate/weak inhibition by (-)-yatein against the 
activity of CYP1A2 for the first time, further strengthens the earlier reports of selectively potent 
inhibition of CYP3A4 by these two phytochemicals (Table 2). 
Having confirmed the identity of seven phytochemicals in the aqueous extract of H. verticillata 
(dried aerial material), and screened them for their impact on the activity of CYP1A2, it appears that 
the bioactivity displayed by the crude aqueous extract of the plant (dried aerial material) can be 
attributed in part to yatein and two of the phytochemicals identified from the mixture of lignans, 
which displayed moderate/weak and moderate inhibition, respectively, of the same enzyme. The 
potential also remains for other unidentified contributors, along with synergistic activities. Whilst 
research on many medicinal plants has been able to identify and link one key phytochemical, or class 
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of phytochemicals, to the bioactivity of a plant, an alternative explanation is that of a synergistic 
effect. This is where a number of phytochemicals act together synergistically to contribute to the 
observed bioactivity, a fact previously noted and attributed to a number of the documented 
pharmacological effects and traditional uses of H. verticillata [41]. Initial attempts made to quantify 
synergy using isobolograms proved inconclusive at this stage, however the investigations would 
benefit with an extension using a wider cocktail of phytochemicals. A growing body of research into 
synergistic effects is reported in the literature [42–44]. Research, and the understanding of synergistic 
effects, is not limited solely to natural products, but is also gaining recognition in the emerging fields 
of network pharmacology and compound synergy [45–48]. 
Table 3. Review of published CYP inhibition research for key phytochemicals. 
Phytochemicals  Reported CYP Inhibition IC50 Value (µM) Reference
Podophyllotoxin CYP3A4  Potent inhibitor (IC50 not stated) [40] 
Dehydropodophyllotoxin  None  -  
Deoxydehydropodophyllotoxin None -  
4′-Demethyldesoxypodophyllotoxin None  -  
4′-Demethylpodophyllotoxin  None  -  
5′-Methoxydehydropodophyllotoxin None  -  
Dehydro-β-peltatin methyl ether  None  -  
(-)-yatein  
CYP3A4 
CYP2D6  
1.0 
95.7 
[39] 
[39] 
Oleanolic acid  
CYP1A2 
CYP2C8/C9/C19 
CYP3A4  
CYP2D6 
143.5 
>500 
78.9 
>500 
[38] 
[38] 
[38] 
[38] 
Ursolic acid 
CYP1A2  
CYP2C8/C9/C19 
CYP3A4  
CYP2D6  
352.4 
>500 
>500 
438.9 
[38] 
[38] 
[38] 
[38] 
Rosmarinic acid  
CYP2C9 
CYP2D6  
CYP3A4  
CYP3A4 
318.9 
>500 
241.2 
No impact 
[49] 
[49] 
[49] 
[50] 
ß-Sitosterol 
CYP2D6 
CYP3A4 
CYP3A4/3A5 
CYP2C19 
>100 
>100 
No impact 
No impact 
[51] 
[51] 
[52] 
[52] 
In conclusion, this research presents the results of an in-depth assessment of the medicinal plant 
H. verticillata, its impact on a number of key CYP450 enzymes, antioxidant properties, and its 
characterisation and further impact on CYP1A2. The results have confirmed the identity of seven 
phytochemicals in the aqueous extract prepared from the dried aerial plant material, five lignans and 
two triterpenes.  
Four traditional preparations of the aerial plant material demonstrated strong antioxidant 
activity, which, together with the plant extracts potent inhibition of known carcinogen activators, 
CYPs 1A1 and 1B1, and previously reported anti-inflammatory and anticancer properties [19] 
warrants further research into the potential chemopreventive properties of this interesting plant, 
bearing in mind the knowledge of its inhibitory impact on drug metabolizing CYP enzymes.  
Screening phytochemicals against the activity of CYP1A2 identified yatein as a moderate-weak 
contributor to the plant’s potent bioactivity, with potential for synergistic activity among other 
constituents. Further analysis on the potential impact of H. verticillata on key drug metabolizing 
enzymes in vivo appears warranted given the extensive use of this plant, both in Jamaica and across 
the Caribbean region.  
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4. Material and Methods  
4.1. Reagents 
CYP substrates and metabolites were purchased from BD Gentest Corporation (Woburn, MA, 
USA). All other chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA), unless 
otherwise stated. β-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of 
dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4′-demethyldesoxypodophyllotoxin, 5′-
methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the 
Department of Chemistry, University of the West Indies, Mona Campus, Jamaica. 4′-Demethyl-
podophyllotoxin and (-)-yatein were purchased from BOC Sciences (New York, NY, USA), oleanolic 
acid, ursolic acid, and rosmarinic acid were purchased from Cayman Chemical (Ann Arbor, MI, USA) 
and podophyllotoxin was purchased from Sigma Aldrich. LC-MS grade high purity water and LC-
MS grade high purity methanol were purchased from Sigma Aldrich (Gillingham, UK). 2,2-diphenyl-
1-picrylhydrazyl (DPPH) was purchased from Sigma Aldrich (St. Louis, MO, USA). 
4.2. Co-Expressed Human CYP Enzymes  
Escherichia coli membranes expressing human CYP1A1, CYP1A2, CYP1B1, CYP3A4, and 
CYP2D6, co-expressed with CYP reductase, were purchased from Cypex Ltd. (Dundee, UK). 
4.3. Preparation of Crude Plant Extracts  
Samples of the plant material were collected, and voucher specimens prepared (voucher number 
35473) and deposited with the Herbarium at the University of the West Indies, Mona, Jamaica, where 
the identity of the plant was confirmed by Mr. Patrick Lewis, botanist and Herbarium Curator.  
4.3.1. Aqueous Extracts—Dried Plant (Leaf and Stem) 
The following method of preparation was previously developed and refined in our laboratory 
[10,16]. Collected leaf and stem plant material was bench-dried in our laboratory and then finely 
crushed using a coffee grinder. The ground plant material was prepared as an infusion following 
traditional Jamaican practices [17,19] using 100 mL of boiled deionized water per 1 g of dried plant 
material and infused for fifteen to twenty minutes. The resulting liquor was suction filtered through 
type 1 Whatman filter paper and centrifuged (MSE Micro Centaur, Sanyo, Osaka, Japan) at 13,000 g 
for five minutes to remove suspended solids. The samples were frozen at −20 °C in round bottom 
flasks and lyophilised using a freeze drier (Labconco, Kansas City, MO, USA). The resulting solids 
were placed in vials and kept at −20 °C until required, and not subjected to more than two freeze-
thaw cycles. 
4.3.2. Aqueous Extracts—Fresh Plant (Leaf and Stem)  
The fresh aerial parts (leaf and stem) of H. verticillata were roughly cut and prepared as infusions 
without drying. All other details of the methodology employed were the same as those detailed 
above.  
4.3.3. Ethanol Extracts—Dried and Fresh Plant (Leaf and Stem) 
Ethanol extracts (tinctures) were prepared from fresh and dried plant material (leaf and stem) 
using documented traditional methods [17,19]. Dried plant material was bench-dried in the 
laboratory, finely chopped in a coffee grinder and placed into a sealable, darkened glass container. 
The tincture was prepared by maceration at room temperature using 10 mL of 75% ethanol (Sigma 
Aldrich, USA) per gram of dried plant material. The sealed container was shaken and turned daily 
for a period of two weeks at room temperature. The resulting liquor was suction-filtered through 
type 1 Whatman filter paper and stored in a sealed darkened glass container. The resulting extract 
was a 1:10 (w/v) (75% EtOH) standard tincture, in which 10 mL of the final preparation is equivalent 
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to 1 g of the dried plant from which the preparation was made. Fresh plant material (leaf and stem) 
was roughly cut and placed into a darkened sealable glass container. The tincture was prepared as 
above. The resulting extract was a 1:10 (w/v) (75% EtOH) specific tincture (fresh plant material).  
4.4. Standardization of Dried Plant Aqueous Extract (Leaf and Stem) by Reversed Phase HPLC (RP-HPLC) 
and LC-MS 
Analysis of H. verticillata was undertaken to characterise the aqueous extract prepared from the 
bench-dried aerial parts (leaf and stem) of the plant. The following chromatographic methods were 
employed. 
4.4.1. High Performance Liquid Chromatography (HPLC) 
RP-HPLC analysis was carried out on a Series 200 instrument (Perkin Elmer, Waltham, MA, 
USA) equipped with a quaternary pump, thermostatted autosampler, column oven, and diode array 
detector. The column used was an RP-18 reversed phase ChromoSep HPLC SS (250 × 4.6 mm, 5 µm) 
(Varian, Palo Alto, CA, USA) including s holder with an Intersil ODS-2 ChromoSep guard column. 
Appropriate methodologies were developed based on previous analysis of the plant in the 
Department of Chemistry, UWI, [20] and on published methodologies for key phytochemicals 
previously identified in the aerial parts of H. verticillata [36,53]. 
4.4.2. Liquid Chromatography—Mass Spectrometry (LC-MS) 
The LC–MS system used comprised a 1260 Infinity LC system (Agilent Technologies, Craven 
Arms, UK) coupled to a 6430 triple quadrupole mass spectrometer (Agilent Technologies). The LC 
system consisted of a 1290 infinity thermostatted autosampler, degasser, binary pumps, and column 
heater. An electrospray ionisation (ESI) source was used for sample analysis. The sample was injected 
through a Zorbax Eclipse plus C18 (2.1 × 100 mm, 1.8 µm) column. The column was heated to 50 °C 
for good reproducibility. The analytical column was connected in tandem with a 0.2 µm inline filter 
to prevent it from blocking. The mobile phase consisted of solvent A, LC-MS grade high purity water 
and solvent B, LC-MS grade high purity methanol. A gradient elution was used for analysis whereby 
20% methanol was run for 2 min and then increased to 60% methanol linearly over 4 min and held 
for 2 min. Methanol was further increased to 80% linearly over 9 min and held for 7 min. The column 
was washed by running 100% methanol for 8 min then decreased to 20% methanol for 2 min to 
equilibrate the column for the next injection. 
The flow rate through the column was set at 0.4 mL/min. The total run time was thirty-four 
minutes. A sample (20 µL) was injected on to the LC-MS system. Auto needle wash was set up to 
remove any carryover effects in the LC analysis. The bypass configurations were set up for the mixer 
and damper with Agilent HPLC 1260 binary pump. This was to convert the pump to low delay 
volume mode and better reproducibility. Both positive and negative ESI were utilised in Full Scan 
mode. Positive ESI was selected for further analysis because it gave more prominent ion peaks in the 
full scan mode. The mass spectrometer was operated in the positive ionization polarity made at a 
spray capillary voltage of 3000 V. Sheath gas temperature and flow were 350 °C &12 L/min resp., 
nozzle voltage was 450 V, drying gas temperature and flow 300 °C & 8 L/min resp., nebulizer gas 
pressure was 25 psi. 
High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer 
(Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 
software using similar HPLC conditions to those described above.  
  
Molecules 2018, 23, 430  12 of 19 
 
4.5. In Vitro Inhibition of CYP Activity 
The following methodology was developed by Crespi et al. [54] and adapted by Shields et al. 
[16] and Murray et al. [15] to screen natural products for cytochrome P450 inhibition potential with a 
particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6. Plant extracts and 
various phytochemicals were evaluated for their ability to inhibit the catalytic activity of human 
cytochrome P450 enzymes by means of high throughput fluorometric inhibition assays conducted in 
96 well microtitre plates as described by Crespi et al., BD Gentest [54] and Murray et al. [15].  
7-Ethoxy-3-cyanocoumarin (CEC) was used as a substrate for detecting the activities of CYPs 
1A1, and 1A2, 7-ethoxyresorufin (ERes) for CYP1B1, 7-benzyloxy-4-trifluoromethylcoumarin (BFC) 
for CYP3A4, and 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin 
(AMMC) for CYP2D6. The reactions were monitored fluorometrically at 37 °C, using an Eclipse 
Fluorescence Spectrophotometer (Varian Cary, Palo Alto, CA, USA). 
4.6. Controls Assessment 
4.6.1. Positive Control Inhibition for CYP450 Assays (CYPs 1A1, 1A2, 1B1, 2D6, 3A4) 
Positive control experiments were conducted with known inhibitors with varying 
concentrations of α-naphthoflavone for CYPs 1A1 and 1B1, furafylline for CYP1A2, quinidine for 
CYP2D6, and ketoconazole for CYP3A4. 
4.6.2. Solvent Impact on CYP1A2 Activity 
In assaying the inhibitory effect of materials on CYP activity, the choice of solvent systems is 
important. The activity of CYP enzymes is known to be significantly inhibited or induced by certain 
non-aqueous solvents at higher concentrations [55,56]. Dimethylformamide (DMF) has been 
identified as one of the least inhibitory solvents towards CYP1A2 [55]. Control assays run with DMF 
confirmed that no inhibition against CYP1A2 occurred at concentrations levels below 3%, 
demonstrating the least impact with no significant levels of inhibition or potentiation of fluorescence 
across the range of concentrations tested. 
4.6.3. Intrinsic Fluorescence 
Each of the various crude extracts, shortlisted phytochemicals and solvents (DMSO, DMF and 
ethanol) were assessed for intrinsic or natural fluorescence to ensure no interference with known 
metabolite fluorescence at each of the relevant excitation and emission wavelengths. 
4.6.4. Metabolite Fluorescence Quenching 
Each of the various crude extracts, shortlisted phytochemicals and solvents (DMSO, DMF and 
ethanol) were investigated for their potential levels of quenching against the fluorescence of each 
known metabolite. Concentrations that resulted in quenching were avoided in subsequent 
screenings.  
4.7. Antioxidant Assay  
The DPPH radical scavenging capacity of extracts of H. verticillata were evaluated by the method 
described by Williams et al. [35]. The electron-donating ability of each extract, at varying 
concentrations, was measured colourimetrically through the bleaching of purple-coloured MeOH 
solution of DPPH. The known antioxidant, ascorbic acid, was used as a positive control.  
Each test extract, as well as the ascorbic acid control, was made up in methanol to a starting 
concentration of 50 µg/mL and serially diluted in ninety-six well microtitre plates. 100 µL of various 
concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 µL of a 
0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol. 
After a thirty-minute incubation period at room temperature, the absorbance was read against a 
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blank, comprising methanol, at 517 nm. All tests were carried out in duplicate for at least two 
independent experiments. 
4.8. Data Analysis 
4.8.1. Measuring Cytochrome P450 Inhibition 
IC50 values (concentration at which 50% of activity remains) were determined by fitting data in 
SigmaPlot (version 10.0), using the four parameter logistic (4PL) non- linear regression model. The 
data listed represent average values from a minimum of two experiments run in triplicate:  
% Enzyme activity = [Min + (Max − Min)/(1+10((LogIC50 − x) × p))]  
where Min and Max are the minimal and maximal observed effects, respectively; x is the 
concentration of test agent; EC50 is the concentration yielding half-maximal response (i.e., IC50); and 
p is the slope parameter. 
4.8.2. Antioxidant Assay 
The level of DPPH inhibition was calculated according to the formula: 
Inhibition (%) = [(Ablank – Asample)/Ablank ] × 100  
where Ablank is the absorbance of the control reaction (containing all reagents except the test 
compound) and Asample is the absorbance of the test compound. 
IC50 values were determined by fitting the data in SigmaPlot (version 10.0, San Jose, CA, USA) 
using the four parameter logistic (4PL) non-linear regression model. An extract concentration 
providing 50% inhibition (IC50) was calculated from the graph plotted as inhibition percentage 
against extract concentration.  
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Appendix A 
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Figure A1. RP-HPLC analysis of reconstituted aqueous extract of H. verticillata (I) with comparison to 
standards: 5 lignan mix (II) [6 mg/mL]; podophyllotoxin (III) [7.8 mM]; (-)-yatein [10 mM] (IV) and 
4′-demethylpodophyllotoxin [2 mM] (V). Separations were achieved using a Perkin-Elmer Series 200 
chromatograph, Waltham, MA, USA fitted with a Chromsep C18, 250 × 4.6 mm, 5 µm column and 
C18 guard column. An injection volume of 20 uL was independently run for H. verticillata (I) and each 
of the standards (II, III, IV and V) for 34 min at a flow rate of 1 mL/min. at wavelength 290 nm at an 
ambient temperature of 18 °C. The mobile phase consisted of methanol and water using gradient 
elution: 20% methanol for 2 min increased to 60% linearly over 4 min and held for 2 min. Methanol 
was further increased to 80% linearly over 9 min and held for 7 min. The column was washed by 
running 100% methanol for 8 min then decreased to 20% to equilibrate the column for the next 
injection. 
 
Figure A2. RP-HPLC analysis of reconstituted aqueous extract of H. verticillata (I) with comparison to 
standard: oleanolic acid (VI) [7.8 mM]. Separations were achieved using a Perkin-Elmer Series 200 
chromatograph, Waltham, MA (USA) fitted with a Chromsep C18, 250 × 4.6 mm, 5 µm column and 
C18 guard column. An injection volume of 20 uL was independently run for H. verticillata (I) and the 
standard (VI) for 34 min at a flow rate of 1 mL/min. at wavelength 290 nm at an ambient temperature 
of 18 °C. The mobile phase consisted of methanol and water using gradient elution: 20% methanol for 
2 min increased to 60% linearly over 4 min and held for 2 min. Methanol was further increased to 80% 
linearly over 9 min and held for 7 min. The column was washed by running 100% methanol for 8 min 
then decreased to 20% to equilibrate the column for the next injection.
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Appendix B 
Table A1. LC-MS and HPLC analysis and summary. 
Phytochemicals Identified in H. 
verticillata 
(Published and Unpublished) 
RP-HPLC 
Standard 
Empirical 
Formula 
m/z—Calculated Value 1
(Difference Between m/z Value and Mono-Isotopic Mass Where the Difference is ≤1.0) 
[M + H] + [M + CH3] + [M + H2O] + [M + Na] + [M + CH3OH] + [M + K] +
Cadina-4,10(15)-dien-3-one (−) C15H22O       
Cadina-10(15)-en-3-one  C15H22O       
Aromadendr-1(10)-en-9-one  C15H22O       
7,11,15-Trimethyl-3-
methylenehexadecane -1,2-diol 
 C20H40O2   330.3 (0.9)    
Rosmarinic acid   C18H16O8     392.3 (0.97)  
Deoxydehydropodophyllotoxin 2 (+) C22H18O7  409.1 (0.1)    433.1 (0.7) 
Dehydrodesoxypodophyllotoxin  C22H18O7  409.1 (0.1)    433.1 (0.7) 
ß-Apopicropodophyllin   C22H20O7    419.0 (0.4)   
Hyptinin  C22H20O7    419.0 (0.4)   
Isodeoxypodophyllotoxin  C22H22O7      437.1 (0.2) 
Deoxypicropodophyllin  C22H22O7      437.1 (0.2) 
4-Demethylpodophyllotoxin (+) C21H20O8   418.1 (0.3)  432.1 (0.3)  
(-)-Yatein (+) C21H20O8   418.2 (0.2)  432.2 (0.2)  
Dehydropodophyllotoxin 2 (+) C22H18O8    433.0 (0.6)    
Podophyllotoxin  (+) C22H22O8   432.1 (0.3) 437.0 (0.3)   
ß-Peltatin   C22H22O8   432.1 (0.3) 437.0 (0.3)   
ß -Sitosterol 3 (−) C29H50O   432.4 (0.0) 437.3 (0.0)   
Oleanolic acid 4 (+) C30H48O3       
1 Mass difference (predicted to measured) in brackets using a High Resolution instrument (Waters LCT ToF MS, with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software); 2 Lignans in the 
five lignan mix supplied by UWI Dept. of Chemistry; 3 Metabolite identified in H. verticillata, but not published at the time of review; 4 Phytochemicals identified through RP-HPLC alone (not LC-
MS); (+)(-) tested and confirmed to be present or absent using HPLC analysis with the relevant standard 
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